IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation

Multi-omics integration analysis robustly predicts high-grade patient survival and identifies CPT1B effect on fatty acid metabolism in Bladder Cancer

(2019) Venkatrao Vantaku et al.   CLINICAL CANCER RESEARCH

A Prospective Targeted Serum Metabolomics Study of Pancreatic Cancer in Postmenopausal Women

(2019) Li Jiao et al.   Cancer Prevention Research

Multiplexing protein and gene level measurements on a single Luminex platform

(2019) Damon B. Cook et al.   METHODS

Ovarian cancer: time to move beyond one size fits all

(2019) Angeles Alvarez Secord   LANCET ONCOLOGY

Ovarian cancer statistics, 2018

(2018) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Tumor-Repopulating Cells Induce PD-1 Expression in CD8 + T Cells by Transferring Kynurenine and AhR Activation

(2018) Yuying Liu et al.   CANCER CELL

IDO decreases glycolysis and glutaminolysis by activating GCN2K, while it increases fatty acid oxidation by activating AhR, thus preserving CD4+ T‑cell survival and proliferation

(2018) Theodoros Eleftheriadis et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

IDO takes a blow

(2018) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Inhibition of the aryl hydrocarbon receptor/polyamine biosynthesis axis suppresses multiple myeloma

(2018) Anna Bianchi-Smiraglia et al.   JOURNAL OF CLINICAL INVESTIGATION

Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond

(2018) Alexander J. Muller et al.   Seminars in Immunopathology

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

(2017) Rebecca Kristeleit et al.   GYNECOLOGIC ONCOLOGY

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

(2017) et al.   JAMA Oncology

AHR Function in Lymphocytes: Emerging Concepts

(2016) Liang Zhou   TRENDS IN IMMUNOLOGY

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

(2016) Vinit Kumar et al.   TRENDS IN IMMUNOLOGY

LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model

(2015) Ruea-Yea Huang et al.   Oncotarget

NAD+ protects against EAE by regulating CD4+ T-cell differentiation

(2014) Stefan G. Tullius et al.   Nature Communications

Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer

(2014) Charlotte S Marcus et al.   Journal of Cancer

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position

(2013) Jason D Buenrostro et al.   NATURE METHODS

Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation

(2012) Feng Qian et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment

(2011) A. M. Lesokhin et al.   CANCER RESEARCH

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

(2011) Christiane A. Opitz et al.   NATURE

Quinolinate phosphoribosyl transferase, a key enzyme in de novo NAD+ synthesis, suppresses spontaneous cell death by inhibiting overproduction of active-caspase-3

(2010) Kazumi Ishidoh et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

MetPA: a web-based metabolomics tool for pathway analysis and visualization

(2010) J. Xia et al.   BIOINFORMATICS

Longitudinal, Noninvasive Imaging of T-Cell Effector Function and Proliferation in Living Subjects

(2010) M. R. Patel et al.   CANCER RESEARCH

An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells

(2010) J. D. Mezrich et al.   JOURNAL OF IMMUNOLOGY

Antigen-Specific Immunity and Cross-Priming by Epithelial Ovarian Carcinoma-Induced CD11b+Gr-1+ Cells

(2010) K. Tomihara et al.   JOURNAL OF IMMUNOLOGY

Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell–like and Foxp3+ regulatory T cells

(2010) Roopali Gandhi et al.   NATURE IMMUNOLOGY

Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

(2010) Junko Matsuzaki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CH223191 Is a Ligand-Selective Antagonist of the Ah (Dioxin) Receptor

(2010) Bin Zhao et al.   TOXICOLOGICAL SCIENCES

Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

(2009) Feng Qian et al.   CANCER RESEARCH

Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma

(2009) Tomoko Inaba et al.   GYNECOLOGIC ONCOLOGY

Evidence for Ligand-Mediated Selective Modulation of Aryl Hydrocarbon Receptor Activity

(2009) I. A. Murray et al.   MOLECULAR PHARMACOLOGY